financetom
Business
financetom
/
Business
/
LuMind IDSC Foundation Merges into the National Down Syndrome Society to Advance Down Syndrome Research and Health Equity
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
LuMind IDSC Foundation Merges into the National Down Syndrome Society to Advance Down Syndrome Research and Health Equity
Sep 30, 2025 9:36 AM

Washington DC, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The National Down Syndrome Society (NDSS) announced that LuMind IDSC Foundation, the nation’s leading Down syndrome and Alzheimer’s disease research organization, is merging into NDSS. For nearly five decades, NDSS has served as the national voice for individuals with Down syndrome and their families, driving advocacy and providing resources across the lifespan. While research was among NDSS’ original priorities, the organization grew, and its focus shifted toward expanding programs and directly supporting families. This merger brings that research focus back under one roof, combining NDSS’ community leadership, reach, and policy influence with LuMind’s research expertise and officially launches a new Research pillar of NDSS. 

 

“This is a historic moment for the Down syndrome community,” said Kandi Pickard, who will continue as CEO of NDSS. “As individuals with Down syndrome face a 90% lifetime risk of developing Alzheimer’s disease with earlier onset and faster progression than the general population, it is critical that families have access to the research-related knowledge, trials, and opportunities they need to thrive. Merging LuMind into NDSS will allow us to build on scientific progress to drive better health outcomes for generations to come.” 

 

This merger provides NDSS with expanded capacity to conduct clinical research projects, create research-related education tools, increase access to breakthrough treatments, educate policymakers about the unique aspects of Down syndrome research, and connect families to opportunities to learn about and participate in the latest research and clinical trials. In addition to Alzheimer’s disease research, the new Research pillar will prioritize health equity campaigns and innovative programs such as CARE Down Syndrome, an online educational initiative that aims to equip primary care providers with the knowledge required to meet the healthcare needs of individuals with Down syndrome. 

“Our mission has always been to accelerate research and empower families,” said Hampus Hillerstrom, current CEO of LuMind who will become President of NDSS. “As part of NDSS, we will continue advancing breakthroughs and delivering real impact for the Down syndrome community through research. We are excited about the increased impact for the Down syndrome community that our larger combined organization can have.” 

 

The merger also resonates personally for NDSS Board Chairman Carlo Frappolli who said, “Alzheimer’s disease isn’t a distant concern for our community. My brother Joe is 62 years old, has Down syndrome, and now suffering from Alzheimer’s disease, with the disease progressing quickly. By merging with LuMind, we are acting now to improve health outcomes for future generations.” 

NDSS’ current programs, advocacy, and community initiatives will remain robust. With the scientific momentum of LuMind, NDSS is poised to create a more equitable future where individuals with Down syndrome have the resources, opportunities, and support they need to thrive throughout their lifetime. The merger will be effective October 1, with public announcements, digital resources, and family outreach rolling out in the weeks ahead. Learn more at https://ndss.org/lumind-joins-ndss. 

### 

About NDSS 

 

The National Down Syndrome Society’s (NDSS) mission is to create a world where individuals with Down syndrome thrive. NDSS advances this mission through its core pillars of Resources & Support, Research, Advocacy & Policy, and Community Engagement. NDSS founded the National Buddy Walk® Program in 1995 and hosts community engagement events throughout the country including the New York City Buddy Walk® and Times Square Video, the NDSS Adult Summit, and the Down Syndrome Advocacy Conference. Visit www.ndss.org to learn more. 

Image: https://www.globenewswire.com/newsroom/ti?nf=OTUzNzc5MCM3MTcyNzc4IzIyMDE1NzI=

Image: https://ml.globenewswire.com/media/OTg4MWYwNDctYTQ5MS00MDUxLWI3NGMtMDI3NjI5MDQ2MDlhLTEyMTMxMjUtMjAyNS0wOS0zMC1lbg==/tiny/National-Down-Syndrome-Society.png Michelle Sagan

National Down Syndrome Society

202 848 5409

[email protected]

Source: National Down Syndrome Society

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hubbell beats quarterly profit estimates, driven by demand in utilities unit
Hubbell beats quarterly profit estimates, driven by demand in utilities unit
Feb 4, 2025
Feb 4 (Reuters) - Electrical equipment maker Hubbell beat estimates for fourth-quarter profit on Tuesday, helped by strong demand in its utility segment for devices used in power grids. Hubbell, which manufactures and sells electrical and utility solutions, has benefitted from ongoing upgrades to the U.S. power grid system. Sales in the company's utilities solutions unit rose 4.4% to $847.1...
Frontdoor to Install Moen's Flo Water Shutoff Valve in 6 Additional US States
Frontdoor to Install Moen's Flo Water Shutoff Valve in 6 Additional US States
Feb 4, 2025
11:16 AM EST, 02/04/2025 (MT Newswires) -- Frontdoor ( FTDR ) said Tuesday it has expanded its partnership with Moen to install the Flo Smart Water Monitor and Shutoff valve in the homes of clients in six additional US states. Financial terms were not disclosed. The company said it is adding Connecticut, Illinois, Kansas, Michigan, New Jersey, and Tennessee to...
Mineralys Completes Enrollment in Mid-Stage Hypertension Trial
Mineralys Completes Enrollment in Mid-Stage Hypertension Trial
Feb 4, 2025
11:20 AM EST, 02/04/2025 (MT Newswires) -- Mineralys Therapeutics ( MLYS ) said Tuesday it has completed enrollment in the phase 2 trial of lorundrostat for the treatment of hypertension in subjects with chronic kidney disease and albuminuria. The clinical-stage biopharmaceutical company said it continues to expect topline data from the trial in Q2 of 2025. Price: 9.92, Change: -0.01,...
Toro's HammerHead Trenchless Acquires ProKASRO Services USA
Toro's HammerHead Trenchless Acquires ProKASRO Services USA
Feb 4, 2025
11:17 AM EST, 02/04/2025 (MT Newswires) -- Toro's (TTC) HammerHead Trenchless division said Tuesday it has acquired ProKASRO Services USA, a provider of robotic solutions and rehabilitation equipment for underground water and wastewater infrastructure repair. Financial details weren't disclosed. HammerHead said it will continue to market trenchless pipe rehabilitation and replacement products under the ProKASRO USA brand, while keeping operations...
Copyright 2023-2026 - www.financetom.com All Rights Reserved